News

UCB partners with Five Prime
Enlarge image

BusinessBelgium

UCB partners with Five Prime

20.03.2013 - Belgian UCB S.A. and US-based biologics specialist Five Prime Therapeutics have entered into a drug discovery collaboration.

The companies will screen for new targets and therapeutics in the areas of fibrosis-related inflammatory diseases and central nervous system (CNS) disorders. Under the terms of the agreement, UCB will gain exclusive access to FivePrime's library of 5.600 functionally secreted proteins and receptor proteins in up to five programmes to identify new targets and disease mechanisms.   

FivePrime will receive US$16m for providing its library and screening platform, a combination of an upfront fee, technology access fees, research funding and success-based research milestone payments. UCB has an option to license exclusively rights to selected protein targets discovered by FivePrime within the collaboration. In addition, FivePrime would be eligible for potential option exercise fees and product-related milestone payments, as well as tiered royalties on global net sales on future products related to each licensed protein.  

Further financial details are subject to a confidentially agreement.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/ucb-partners-with-five-prime-therapeutics.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOTEC3.94 EUR8.54%
  • VITA 343.90 EUR4.00%
  • SANTHERA86.50 CHF3.59%

FLOP

  • WILEX2.30 EUR-2.54%
  • 4SC1.22 EUR-2.40%
  • ADDEX3.99 CHF-1.97%

TOP

  • SANTHERA86.50 CHF35.2%
  • BB BIOTECH144.50 EUR8.9%
  • ADDEX3.99 CHF4.5%

FLOP

  • WILEX2.30 EUR-23.1%
  • 4SC1.22 EUR-15.9%
  • MOLOGEN7.84 EUR-13.8%

TOP

  • SANTHERA86.50 CHF3612.4%
  • CO.DON2.57 EUR221.2%
  • PAION2.46 EUR182.8%

FLOP

  • CYTOS0.26 CHF-93.4%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014